Skip to content

Study · Not a test of the peptide alone · 1988

3 results

Applications of BOP reagent in solid phase synthesis. Advantages of BOP reagent for difficult couplings exemplified by a synthesis of [Ala 15]-GRF(1-29)-NH2.

Fournier A, Wang CT, Felix AM

International journal of peptide and protein research1 Jan 1988Cited by 37 (Europe PMC)

PMID2896637 (opens in a new tab)DOI10.1111/j.1399-3011.1988.tb00010.x (opens in a new tab)PepBankPUB-02896637
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 01LabNot a test of Sermorelin aloneIn vitro (cell-free)Other

    In solid-phase synthesis of [Ala15]-GRF(1-29)-NH2 fragments, single BOP couplings gave superior yields compared with multiple DCC couplings.

    In plain wordsIn lab chemistry, a coupling reagent called BOP gave higher yields of peptide fragments than the older DCC method.

    Peptide
    Sermorelin
    Outcome
    IncreaseFragment yield with BOP coupling
    Study

    n: not reported in source

    Comparator
    DCC coupling method
    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    The yields of the fragments were superior and the purities comparable using the BOP procedure (single couplings) to those observed using multiple couplings via the DCC coupling method.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02LabNot a test of Sermorelin aloneIn vitro (cell-free)Other

    In solid-phase synthesis of [Ala15]-GRF(1-29)-NH2 fragments, the purities with BOP were comparable to those with multiple DCC couplings.

    In plain wordsIn lab chemistry, peptide fragments made with BOP had similar purity to those made with the older DCC method.

    Peptide
    Sermorelin
    Outcome
    No significant changeFragment purity with BOP coupling
    Study

    n: not reported in source

    Comparator
    DCC coupling method
    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    The yields of the fragments were superior and the purities comparable using the BOP procedure (single couplings) to those observed using multiple couplings via the DCC coupling method.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  3. 03LabNot a test of Sermorelin aloneIn vitro (cell-free)Other

    A total synthesis of [Ala15]-GRF(1-29)-NH2 by BOP coupling gave a product comparable to a control made with multiple DCC couplings.

    In plain wordsIn lab chemistry, the full peptide made with BOP was comparable to the one made with the older DCC method.

    Peptide
    Sermorelin
    Outcome
    No significant changeTotal synthesis product quality
    Study

    n: not reported in source

    Comparator
    DCC coupling method
    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    A total synthesis of [Ala15]-GRF(1-29)-NH2 was also carried out using the BOP procedure
    1 context sentence
    Summary · context
    The resultant GRF(1-29) analog was comparable to a control prepared with multiple DCC couplings under optimized conditions.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.